A
AHMED SAID NEXTRNA THERAPEUTICS
NextRNA is uniquely positioned to deliver transformative small molecule therapeutics targeting long non-coding RNAs. long non-coding RNAs,
Country/Area ：United States
Company Email ：info@nextrna.com
Industry ：HealthcareDrug Manufacturing & ResearchPharmaceuticals
Company address ：650 E Kendall St, Cambridge, Massachusetts, 02142, United States
Company website ：*****
Company phone ：(617) 412-6117
Established ：2021
Company Revenue ：$998,000
Number of employees ：26
SIC Code ：87873
NAICS Code ：54541
Company News
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
Sep 26, 2023
BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of long non-coding RNAs (lncRNAs) to develop transformative medicines for multiple diseases with an initial focus on oncology and neurology, today announced the appointment of Lori Friedman, PhD, to its Board of Directors. Dr. Friedman is currently Chief Scientific Officer of ORIC Pharmaceuticals, Inc. and formerly served as head of translational oncology for Genentech Research and Early Development (
Sep 26, 2023
NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery SummitDec 8, 2022
BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, today announced that Dominique Verhelle, Ph.D., Co-Founder, Chief Executive Officer and Chief Scientific Officer, will give a corporate presentation at the 5th Annual RNA-Targeted Drug Discovery Summit, which will be held December 13 – 15, 2022 in Boston. Dr. Verhelle’s presentation, which is scheduled to take place on Thursday, Dece
Dec 8, 2022NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines ConferenceSep 22, 2022
BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, today announced management’s participation in two upcoming investor conferences. BioPharm America September 28 – 29, 2022 Boston (In-person event) JS Cleiftie, MS, MBA, Chief Business Officer and Head of Finance Available for one-on-one meetings Chardan’s 6th Annual Genetic Medicines Conference October 3 – 4, 2022 NYC (In-person even
Sep 22, 2022NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership TeamAug 11, 2022
BOSTON--(BUSINESS WIRE)--NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive Officer. Dominique is a co-founder of NextRNA who has led the scientific and corporate strategy since its launch over the past year and a half. “Dominique is an exceptional leader who brings over 20 years of R&D, company building, and management expe
Aug 11, 2022NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to PatientsMar 1, 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextRNA Therapeutics today announces its launch with $9.3 million in seed financing and a $46.8 million Series A.
Mar 1, 2022Web Summary
Q1: What is the address of NextRNA Therapeutics' headquarters?
A1: The address of NextRNA Therapeutics' headquarters is 40 Guest St., Boston, MA 02135.
Q2: What type of products does NextRNA Therapeutics develop?
A2: NextRNA Therapeutics develops small molecule therapeutics targeting long non-coding RNAs (lncRNAs) with a primary focus on oncology and neuroscience.
Q3: In which industry is NextRNA Therapeutics operating?
A3: NextRNA Therapeutics operates in the biotechnology industry, specifically in the field of RNA-based therapeutics.
Q4: What services does NextRNA Therapeutics offer?
A4: As a biotechnology company, NextRNA Therapeutics offers various services including therapeutic application development, partnership opportunities, and scientific advisory services.
Q5: How can one contact NextRNA Therapeutics for general inquiries or media relations?
A5: One can contact NextRNA Therapeutics through their general email address info@nextrna.com or by calling +1-617-545-7707. For media-related inquiries, they have a dedicated email address PR@nextrna.com.
Q6: What is the name of the CEO and Co-Founder of NextRNA Therapeutics?
A6: The CEO and Co-Founder of NextRNA Therapeutics is Dominique Verhelle, PhD, MBA.
Q7: Who are some of the key partners or collaborators of NextRNA Therapeutics in the oncology field?
A7: NextRNA Therapeutics has partnered with Bayer to develop small molecule therapeutics targeting long non-coding RNAs (lncRNAs) in oncology. This partnership is worth over $500 million.
Q8: What is the focus area of NextRNA Therapeutics' research and development efforts?
A8: The focus area of NextRNA Therapeutics' research and development efforts is on developing transformative small molecule therapeutics targeting dysregulated long non-coding RNAs (lncRNAs) that recruit RNA-binding proteins (RBPs) to drive pathological processes across disease areas.
A1: The address of NextRNA Therapeutics' headquarters is 40 Guest St., Boston, MA 02135.
Q2: What type of products does NextRNA Therapeutics develop?
A2: NextRNA Therapeutics develops small molecule therapeutics targeting long non-coding RNAs (lncRNAs) with a primary focus on oncology and neuroscience.
Q3: In which industry is NextRNA Therapeutics operating?
A3: NextRNA Therapeutics operates in the biotechnology industry, specifically in the field of RNA-based therapeutics.
Q4: What services does NextRNA Therapeutics offer?
A4: As a biotechnology company, NextRNA Therapeutics offers various services including therapeutic application development, partnership opportunities, and scientific advisory services.
Q5: How can one contact NextRNA Therapeutics for general inquiries or media relations?
A5: One can contact NextRNA Therapeutics through their general email address info@nextrna.com or by calling +1-617-545-7707. For media-related inquiries, they have a dedicated email address PR@nextrna.com.
Q6: What is the name of the CEO and Co-Founder of NextRNA Therapeutics?
A6: The CEO and Co-Founder of NextRNA Therapeutics is Dominique Verhelle, PhD, MBA.
Q7: Who are some of the key partners or collaborators of NextRNA Therapeutics in the oncology field?
A7: NextRNA Therapeutics has partnered with Bayer to develop small molecule therapeutics targeting long non-coding RNAs (lncRNAs) in oncology. This partnership is worth over $500 million.
Q8: What is the focus area of NextRNA Therapeutics' research and development efforts?
A8: The focus area of NextRNA Therapeutics' research and development efforts is on developing transformative small molecule therapeutics targeting dysregulated long non-coding RNAs (lncRNAs) that recruit RNA-binding proteins (RBPs) to drive pathological processes across disease areas.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
